Print this page for your doctor
CLINICAL TRIAL SUMMARY
MDACC Study No:
(clinicaltrials.gov NCT No:
A Phase I, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to find the highest tolerable dose
of IGN523 that can be given to patients with relapsed or refractory AML. The
safety of this drug will also be studied.
This is the first study using IGN523 in humans.
Phase of Study:
Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Igenica Biotherapeutics, Inc.
Study Contact Information
For Clinical Trial Enrollment:
For General Questions about Clinical Trials:
Study Objectives / Outcomes
Study Status Information
Resources and Links
Return to List